{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:31:11Z","timestamp":1761611471277},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The efficiency and tolerance of long-term adjuvant imatinib treatment for patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor (GIST) was unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 45-year-old man underwent complete resection of an intestinal GIST in August 2001. Four years later, a giant (11\u200a\u00d7\u200a8\u200a\u00d7\u200a6\u200acm) recurrent GIST located in the retroperitoneum was detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The recurrent tumor was positive for CD117 by immunohistochemistry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The recurrent tumor was completely resected after 4 months of effective imatinib treatment (400\u200amg\/day), and the patient continued imatinib treatment postoperatively. In June 2011, imatinib treatment was stopped for 3 weeks because of hepatitis B infection, and resumed with a reduced dose level of 300\u200amg\/day when liver function recovered. In March 2017, imatinib treatment was interrupted again for 12 days because the patient underwent cholecystectomy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>In December 2017, a computed tomography scan showed no signs of tumor recurrence. To date, the patient has been under adjuvant imatinib treatment for &gt;12 years without severe side effects. The plasma concentration of imatinib (detected in February 2018) was trough concentration (C<jats:sub>min<\/jats:sub>) 1015.7\u200ang\/mL and peak concentration (C<jats:sub>max<\/jats:sub>) 1550.5\u200ang\/mL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case report highlights the active role of long-term (&gt;12 years) imatinib treatment after complete resection of localized recurrent GIST.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014477","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T08:56:52Z","timestamp":1549529812000},"page":"e14477","source":"Crossref","is-referenced-by-count":5,"title":["Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment"],"prefix":"10.1097","volume":"98","author":[{"given":"Welda E.H.","family":"Tjhoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-hui","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-ren","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"281","DOI":"10.21147\/j.issn.1000-9604.2017.04.01","article-title":"Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor","volume":"29","author":"Li","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","article-title":"Risk stratification of patients diagnosed with gastrointestinal stromal tumor","volume":"39","author":"Joensuu","year":"2008","journal-title":"Hum Pathol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2006.09.0183","article-title":"Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group","volume":"25","author":"Blay","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21037\/tgh.2018.02.02","article-title":"Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?","volume":"3","author":"Kikuchi","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1080\/00365520701206779","article-title":"Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy","volume":"42","author":"Yu","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1477-7819-10-111","article-title":"Surgery after treatment with imatinib and\/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?","volume":"10","author":"Tielen","year":"2012","journal-title":"World J Surg Oncol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/annonc\/mdp310","article-title":"Post-imatinib surgery in advanced\/metastatic GIST: is it worthwhile in all patients?","volume":"21","author":"Mussi","year":"2010","journal-title":"Ann Oncol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1245\/s10434-014-4360-8","article-title":"Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)","volume":"22","author":"Rubio-Casadevall","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1245\/s10434-014-3866-4","article-title":"The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses","volume":"21","author":"Park","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","article-title":"Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2014analysis of prognostic factors (EORTC-STBSG collaborative study)","volume":"40","author":"Bauer","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00432-016-2334-x","article-title":"Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up","volume":"143","author":"Lin","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2018.03.01","article-title":"Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study","volume":"3","author":"Cameron","year":"2018","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R17-20230914","first-page":"2636","article-title":"Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"R18-20230914","first-page":"3629","article-title":"Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor","volume":"34","author":"Walker","year":"2014","journal-title":"Anticancer Res"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14639230500236818","article-title":"Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment","volume":"47","author":"Ikeda","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.029","article-title":"Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting","volume":"57","author":"Bouchet","year":"2016","journal-title":"Eur J Cancer"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"e5488","DOI":"10.1097\/MD.0000000000005488","article-title":"A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment","volume":"95","author":"Yin","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201902080-00097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T20:09:26Z","timestamp":1694722166000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201902080-00097"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014477","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}